HOXB13 and prostate cancer: Clinical phenotype was not significantly different for HOXB13 carriers compared with the BRCAX group when comparing low-risk D’Amico (p = 0.3), patients with Grade Group 1 and 2 disease (p = 0.3), PSA (p = 0.5), age at death (p = 0.1), age at diagnosis (p = 0.8) and prostate-cancer-specific death (p = 0.4).